You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

THYREL TRH Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Thyrel Trh, and what generic alternatives are available?

Thyrel Trh is a drug marketed by Ferring and is included in one NDA.

The generic ingredient in THYREL TRH is protirelin. There are four drug master file entries for this compound. Additional details are available on the protirelin profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for THYREL TRH?
  • What are the global sales for THYREL TRH?
  • What is Average Wholesale Price for THYREL TRH?
Summary for THYREL TRH
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 71
Patent Applications: 3,200
DailyMed Link:THYREL TRH at DailyMed
Drug patent expirations by year for THYREL TRH

US Patents and Regulatory Information for THYREL TRH

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring THYREL TRH protirelin INJECTABLE;INJECTION 018087-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

THYREL TRH Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Thyrel TRH (Protirelin)

Introduction

Thyrel TRH (protirelin) is a diagnostic agent used primarily to assess thyroid, pituitary, or hypothalamic dysfunction. Despite its specific uses, the market dynamics and financial trajectory of Thyrel TRH are influenced by several factors, including regulatory changes, clinical utility, and market competition.

Clinical Uses and Indications

Thyrel TRH is indicated as an adjunctive agent in the diagnostic assessment of thyroid function and in evaluating pituitary or hypothalamic dysfunction. It is used to assess the effectiveness of thyrotropin suppression, adjust thyroid hormone dosage in primary hypothyroidism, and differentiate between various forms of hypothyroidism[2].

Market Availability and Production Issues

In 2002, the production of Thyrel TRH was halted by Ferring Pharmaceuticals to modify the manufacturing process to meet new production guidelines. This halt was significant because no other company was producing TRH at that time, leading to a temporary absence of the product in the market. The return of Thyrel TRH to the market has been delayed, and the exact timeline for its reintroduction remains uncertain[1].

Impact of Regulatory Changes

The temporary removal of Thyrel TRH from the market highlights the impact of regulatory changes on its availability and use. New production guidelines and the need for compliance have forced manufacturers to invest time and resources into modifying their processes. This has created a gap in the market that other diagnostic agents may fill, potentially affecting the financial trajectory of Thyrel TRH upon its return[1].

Clinical Utility and Diagnostic Value

Despite the limited indications for TRH due to the development of ultrasensitive TSH assays, Thyrel TRH still holds value in special clinical situations. It is useful in distinguishing TSH-secreting pituitary tumors from other forms of inappropriate TSH secretion and in diagnosing subtle cases of central hypothyroidism. However, its utility is largely adjunctive, meaning it is used in conjunction with other diagnostic procedures[1][2].

Side Effects and Safety Profile

The safety profile of Thyrel TRH includes minor side effects reported in about 50% of patients, such as marked changes in blood pressure, breast enlargement, and leakage in lactating women. These side effects are generally transient and do not significantly impact the drug's overall safety profile. However, they must be considered in the broader context of patient care and treatment decisions[2].

Market Competition

The diagnostic market for thyroid function is highly competitive, with various tests and agents available. The absence of Thyrel TRH from the market has likely shifted demand to other diagnostic tools, potentially eroding its market share. Upon its return, Thyrel TRH will need to compete with established alternatives that may have filled the gap during its absence.

Financial Trajectory

The financial trajectory of Thyrel TRH is challenging to predict due to its temporary removal from the market. Here are some key points to consider:

Revenue Impact

The halt in production has resulted in a loss of revenue for Ferring Pharmaceuticals. The duration of this halt and the time required to implement manufacturing changes will continue to affect the company's financials.

Market Share

Upon its return, Thyrel TRH may face difficulties in regaining its previous market share due to the presence of alternative diagnostic agents. This could impact its revenue and profitability.

Research and Development

Investments in research and development to improve the manufacturing process and comply with regulatory guidelines will be necessary. These costs will be factored into the overall financial trajectory of the drug.

Future Prospects

Despite the current challenges, there are potential future prospects for Thyrel TRH:

Therapeutic Applications

Research suggests that TRH may have therapeutic effects beyond its diagnostic use, such as in inflammatory disorders and neuroprotection. Expanding its indications could enhance its market value and financial performance[4][5].

Market Demand

The ongoing need for precise diagnostic tools in endocrinology ensures a demand for agents like Thyrel TRH. If the product can be reintroduced efficiently and effectively, it may regain its position in the market.

Key Takeaways

  • Regulatory Compliance: The temporary removal of Thyrel TRH highlights the importance of regulatory compliance in pharmaceutical manufacturing.
  • Clinical Utility: Despite limited indications, Thyrel TRH remains valuable in specific clinical situations.
  • Market Competition: The absence of Thyrel TRH has allowed other diagnostic agents to fill the gap, potentially impacting its market share upon return.
  • Financial Impact: The halt in production has resulted in revenue loss, and the financial trajectory will depend on the successful reintroduction and market acceptance of the drug.
  • Future Prospects: Potential therapeutic applications and ongoing market demand offer opportunities for growth.

FAQs

What is Thyrel TRH used for?

Thyrel TRH (protirelin) is used as a diagnostic agent to assess thyroid, pituitary, or hypothalamic dysfunction. It is particularly useful in evaluating the effectiveness of thyrotropin suppression and adjusting thyroid hormone dosage in primary hypothyroidism[2].

Why was Thyrel TRH temporarily removed from the market?

Thyrel TRH was temporarily removed from the market in 2002 to modify the manufacturing process to meet newly mandated production guidelines[1].

What are the common side effects of Thyrel TRH?

Common side effects include marked changes in blood pressure, breast enlargement, and leakage in lactating women. These side effects are generally minor and transient[2].

How does the absence of Thyrel TRH affect the market?

The absence of Thyrel TRH has allowed other diagnostic agents to fill the gap, potentially impacting its market share upon its return. This shift in demand could erode its market position[1].

What are the potential future prospects for Thyrel TRH?

Thyrel TRH may have future prospects in therapeutic applications beyond its diagnostic use, such as in inflammatory disorders and neuroprotection. Successful reintroduction and market acceptance could also enhance its financial performance[4][5].

Sources

  1. Thyroid.org: Thyrel® TRH Temporarily Removed from Market
  2. RxList: Thyrel Trh (Protirelin): Side Effects, Uses, Dosage
  3. GlobeNewswire: Global Human Growth Hormones Market to Reach USD 10 Billion by 2030
  4. PubMed: The thyrotropin-releasing hormone (TRH)-immune system
  5. MDPI: New Efforts to Demonstrate the Successful Use of TRH as a Therapeutic Agent

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.